Kornimate/medical-research-clean huggingface dataset:
associations between neck muscle fatigue, joint position sense, and headache in cervicogenic headache

Conditions: Cervicogenic Headache

Summary: this research study aims to better understand the relationships between neck muscle function, neck joint position sense, and headache pain and disability in people with chronic cervicogenic headache. cervicogenic headache is headache originating from the neck area. participants will fill out questionnaires about their headache pain and ability to do daily activities. they will also do tests to measure neck muscle fatigue and neck joint position sense. researchers will analyze if those with more neck muscle fatigue and poorer joint position sense have worse headache pain and disability. the results may improve understanding of cervical spine factors related to cervicogenic headache. this could help guide more targeted treatment approaches.

chronic cervicogenic headache (cgh) is characterized by chronic headache originating from the upper cervical spine and occipital region. cgh is associated with impairments in cervical muscular control and proprioception or joint position sense. however, relationships between these cervical impairments and headache symptoms are not fully elucidated. this cross-sectional quantitative study aims to investigate associations between neck flexor muscle fatigue, cervical joint position sense, and clinical headache parameters like pain and disability in individuals with cgh. a sample of 30 adults ages 18-65 years old with cgh longer than 3 months duration and more than 15 headache days per month will be recruited from neurology clinics. participants will attend a single 2 hour study visit.

Eligibility criteria:
inclusion criteria: * ages 18-60 years * chronic cgh (\>3 months duration) * headache frequency ≥15 days/month exclusion criteria: * cervical nerve root compression or other specific pathologies explaining headache * history of cervical spine surgery * botulinum toxin injections in cervical musculature in past 6 months
the immediate and longterm immune responses of uk infants and young children to a booster dose of hib vaccine

Conditions: Haemophilus Influenzae Type b

Summary: to measure the magnitude and persistence of the antibody response to a booster dose of hib conjugate vaccine given between 9 months and 4 years of age to uk children who had completed primary immunisation with 3 doses of hib vaccine given at 2/3/4 months of age either as a combined d/t/wholecellpertussis/hib or d/t/acellularpertussis/hib vaccine.


Eligibility criteria:
inclusion criteria: * written informed consent from parent or legal guardian of the infant or child * age \>= 9 months and \<4 years at recruitment * eligible to receive a single dose of hib vaccine as per the uk schedule * receipt of three doses of hib vaccine in infancy exclusion criteria: * history of hib infection * history of severe local reaction that can be confidently related to a prior hib immunisation * deferral of vaccination if acute illness and/or temperature \>38c on day of vaccination
vitamin d3 in sensory recovery after digital nerve suture (d3nerv).

Conditions: Digital Nerve Injury

Summary: digital nerve injuries are frequent in a fesum center (federation européenne des services d'urgences mains), and they need to be repaired in order to reduce the risk of hypoesthesia and to prevent painful neuroma. several animal studies have shown that cholecalciferol improves axonal nerve regeneration and myelination. no study has ever been done on human subjects to evaluate the nerve regeneration after cholecalciferol supplementation. our hypothesis is that cholecalciferol supplementation could improve axonal nerve regeneration and myelination after traumatic digital nerve injuries treated by microsurgical sutures and reduce the risk of hypoesthesia and neuroma.


Eligibility criteria:
inclusion criteria: * affiliated to social security scheme, * wound of the palmar hand with isolated digital nerve section, requiring digital nerve microsurgical suture in the operating room by a senior surgeon, * signing a free and informed consent and well-informed of the study and procedure. exclusion criteria: * ischemia, * multiple lesion of the same nerve, * pregnant or nursing women, * contraindication of cholecalciferol : known hypersensitivity, any history of hypercalcemia, hypercalciuria or renal lithiasis, * cholecalciferol supplementation in the past 6 months, * lesion of the same controlateral finger, * history of nerve lesion or hypoesthesia on the same finger, * history of previous neurological disorders with upper limb sensitivity disorder, * impossibility to undergo the medical follow-up because of geographical, social or psychological reason, * participation in another clinical trial that does not allow simultaneous participation in several clinical trials, * orlistat® treatment, * history of celiac disease.

Keywords: digital nerve injury neuroma cholecalciferol
pilot study of cognitive assessment in welsh speakers

Conditions: Cognitive Impairment - e.g. Dementia

Summary: 19% of wales' population speaks welsh. under the welsh language act 1993, every public body providing services to the public in wales has to prepare a scheme setting out how it will provide those services in welsh. diagnosing dementia requires a comprehensive assessment, an essential component of which is a cognitive assessment tool, which takes the form of a questionnaire. in clinical practice, this is currently only available through the medium of english. the investigators objective is to measure the difference between cognitive assessment scores (using the montreal cognitive assessment (moca)), when done in english and welsh, in those who are cognitively impaired and whose first language is welsh. the investigators predict that there will be a significant difference in scores in favour of the welsh-medium tests, thus proving that the current mode of administering the test is prejudiced against patients whose first language is welsh. if the investigators predictions are correct, then the investigators would seek to introduce a validated welsh-language cognitive assessment tool to the domain of the welsh nhs.


Eligibility criteria:
inclusion criteria: * welsh speakers - self-identify as first-language welsh * diagnosis of dementia - recorded in patient's case notes exclusion criteria: * refusal * intercurrent illness * blind/any other disability which may prevent participant from fully completing cognitive assessment
gemcitabine and cisplatin in treating patients with refractory or recurrent cancer of the cervix

Conditions: Cervical Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: phase ii trial to study the effectiveness of combining gemcitabine and cisplatin in treating patients who have refractory or recurrent cancer of the cervix.

objectives: * determine the antitumor activity of gemcitabine and cisplatin in patients with refractory or recurrent squamous cell carcinoma of the cervix. * determine the nature and degree of toxicity of this regimen in these patients. outline: this is a multicenter study. patients receive cisplatin iv and gemcitabine iv over 1 hour on days 1 and 8. treatment continues every 28 days in the absence of disease progression or unacceptable toxicity. patients are followed every 3 months for 2 years and then every 6 months for 3 years. projected accrual: a total of 28-69 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed refractory or recurrent squamous cell carcinoma of the cervix that has failed local therapy and is considered incurable * must have had 1 prior chemotherapy regimen for cervical cancer * no more than 1 prior chemotherapy regimen (single or combination drug therapy), unless used as a radiosensitizer * no prior chemotherapy for recurrent or persistent disease including retreatment with initial chemotherapy * bidimensionally measurable disease * ineligible for higher priority gog protocol patient characteristics: age: * not specified performance status: * gog 0-2 life expectancy: * not specified hematopoietic: * platelet count at least lower limit of normal * absolute neutrophil count at least 1,500/mm\^3 hepatic: * bilirubin no greater than 1.5 times normal * sgot and alkaline phosphatase no greater than 3 times normal renal: * creatinine no greater than 2.0 mg/dl other: * not pregnant * fertile patients must use effective contraception * no significant infection * no other malignancies within past 5 years except nonmelanoma skin cancer prior concurrent therapy: biologic therapy: * at least 3 weeks since prior biologic therapy for cervical cancer chemotherapy: * see disease characteristics * at least 3 weeks since prior chemotherapy for cervical cancer and recovered * no prior gemcitabine endocrine therapy: * at least 3 weeks since prior endocrine therapy for cervical cancer radiotherapy: * at least 3 weeks since prior radiotherapy for cervical cancer and recovered * no prior radiotherapy to more than 25% of marrow-bearing areas surgery: * at least 3 weeks since prior surgery for cervical cancer and recovered other: * no concurrent amifostine or other protective reagents * no prior anticancer therapy that contraindicates study

Keywords: recurrent cervical cancer stage ivb cervical cancer stage iva cervical cancer cervical squamous cell carcinoma
surgical infection rates with adjunct vancomycin compared to standard peri-operative iv antibiotics

Conditions: Lumbar Pain

Summary: determine the effect of vancomycin powder added to the surgical wound at closure on surgical infection rates.

study will be blinded and randomized 1:1 to either vancomycin powder at closure or no vancomycin powder at closure.

Eligibility criteria:
inclusion criteria: * all adult, 18 years or greater undergoing posterior approach spinal surgery exclusion criteria: * prisoner, pregnant women, patient under the age of 18, those of diminished decision making capacity. * patients with known reaction to vancomycin. * patients having surgery specifically for spine infection * patients having adcf or alif

Keywords: posterior spine surgery infection vancomycin surgical wound infection
china rural hypertension control project 2014

Conditions: Hypertension

Summary: china rural hypertension control (crhc) project is a cluster randomized trial aims to test the effectiveness of a standardized protocol-based treatment program on hypertension control in rural china.


Eligibility criteria:
inclusion criteria: * man and women aged 40 years or older. * mean systolic blood pressure ≥140 mm hg and/or diastolic blood pressure ≥90 mm hg; and/or use of antihypertensive medications.mean blood pressure is based on three measurements at two separate days at least two days apart and within one month. * permanent residents in the study villages. * do not plan to emigrate in the next 2 years. exclusion criteria: * unable to provide consent. * treated for malignant tumor and life expectancy\<2 years judged by study physician. * pregnancy, currently trying to become pregnant, or of child-bearing potential and not using birth control. * diagnosted psychiatric patients.

Keywords: hypertension rural china protocol-based treatment
prevalence of contrast enhancement of the oculomotor nerve on 3d pd t1 mri sequence in patients with ophthalmoplegia

Conditions: Ophthalmoplegia

Summary: oculomotor nerve (third cranial nerve or "iii") palsy is a relatively frequent cause of consultation in ophthalmology. it may reveal a life-threatening pathology such as aneurysm rupture, pituitary apoplexy, and therefore need imaging in emergency. apart from few extreme emergency situations, mri of the oculomotor tract is the first-line examination required. in our usual clinical practice, we noticed in several patients unusual contrast enhancement within the oculomotor nerve on t1 sequence with gadolinium injection, observed in various locations along the nerve path (cavernous and/ or intra-orbital segment). this contrast enhancement, could confirm the nerve impairment this study aims to analyse the efficiency of a new sequence 3d pd t1 which isotropic spatial resolution less than 1mm, not yet described in the literature, to depict this enhancement. in patients with ophthalmoplegia involving probably the third cranial nerve, disclosing this mri sign could help (i) to confirm the involvement of the oculomotor nerve and eliminate differential diagnoses such as myasthenia (ii) to orientate the etiological diagnosis (inflammatory or ischemic origin). this new sequence 3d pd t1 sequence focused on the iii could thus be systematically included in the usual mri protocol.


Eligibility criteria:
inclusion criteria: - ophthalmoplegia whatever the clinical form (unilateral or not, isolated or not, sudden or progressive onset) exclusion criteria: -absolute contraindication to mri or injection of contrast agents.
treatment outcome of autologous prp versus conventional therapy among patients with chronic venous leg ulcers

Conditions: Venous Leg Ulcer

Summary: the use of prp has dramatically increased in the fields of orthopedics, spine surgery, reconstructive plastic surgery, oral and maxillofacial surgery, and dermatological indications. nonetheless, its use in the treatment of wounds is not as widespread as in other fields. in this experimental study, the treatment outcome of autologous prp was assessed in comparison to conventional therapy among patients with chronic venous leg ulcers.

venous ulcers are the most common form of leg ulcers which have a significant impact on quality of life and work productivity. in addition, the costs associated with the long-term care of these chronic wounds are substantial. conventional therapies such as dressings, surgical debridement, compression bandage, and even skin grafting cannot provide satisfactory healing since these treatments are not able to provide necessary growth factors that can modulate healing processes. autologous platelet-rich plasma (prp) is a safe, simple, affordable, and less expensive procedure in the treatment of chronic ulcers with reportedly good results. since it is an autologous method, it is biocompatible and safe. data from this would help in establishing it as a treatment of choice, thereby leading to a reduction in cost and benefiting the patient both financially and psychologically. prp is a volume of autologous plasma that has a platelet concentration above baseline i.e., five times more than normal platelet counts. prp enhances wound healing by promoting the healing process by seven growth factors present in it. they are platelet-derived growth factor (αα, αβ, αβ), fibroblast growth factor, vascular endothelial growth factor, epidermal growth factor, and transforming growth factor. these growth factors are important in modulating mesenchymal cell recruitment, proliferation, and extra-cellular matrix synthesis during the healing process.

Eligibility criteria:
inclusion criteria: * patients aged 30-80 years of any gender presented with chronic venous leg ulcers exclusion criteria: * patients with history of peripheral arterial disease. * patients with history of acute venous thromboembolism. * patients with platelet count less than 150000. * patients with history of bleeding disorders. * patients with history of osteoporosis. * patients with history of peripheral neuropathy. * pregnant patients assessed by history and confirmed by dating scan. * patients with history of congestive cardiac failure, chronic liver disease, asthma, copd, or stroke.
vascular sensitivity to adrenergic agonists in patients with chf and in healthy subjects

Conditions: Congestive Heart Failure

Summary: congestive heart failure (chf) is asociated with changes in cardiac function and vascular responses. the aim of this study is to characterize these differences. our hypothesis is, that there are differences in vascular responses between healthy subjects and patients with chf.


Eligibility criteria:
inclusion criteria: * patients with congestive heart failure nyha i-ii * stable clinical condition exclusion criteria: * resting systolic blood pressure \< 100 * resting heart rate \< 50 * hypersensitivity to dexmedetomidine, phenylephrine, isoproterenol, terbutaline
a study of selexipag assessing right ventricular remodeling in pulmonary arterial hypertension by cardiac magnetic resonance imaging

Conditions: Pulmonary Arterial Hypertension

Summary: the purpose of the study is to assess the effects of selexipag on right ventricular (rv) function in participants with pulmonary arterial hypertension (pah).


Eligibility criteria:
inclusion criteria: * world health organization functional class (who fc) ii or iii. enrollment will be stratified by who fc ii or iii. proportion of participants with who fc ii and who fc iii are expected to be approximately 40 percent (%) and 60%, respectively * pulmonary arterial hypertension (pah) etiology belonging to one of the following groups according to 6th world symposium of pulmonary hypertension (wsph) classification: a) idiopathic pah, b) heritable pah, c) drugs or toxins induced d) pah associated with connective tissue disease, e) pah associated with congenital heart disease, with simple systemic-to-pulmonary shunt at least 1 year after surgical repair * patients already receiving pah-specific oral mono or dual therapy (that is, phosphodiesterase type 5 inhibitors \[pde-5i\] or soluble guanylate cyclase stimulators \[sgcs\] and/or endothelin receptor antagonist \[era\]) or patients who are not candidates for these therapies * n-terminal-pro-hormone brain natriuretic peptide (nt-probnp) greater than or equal to (\>=) 300 nanograms per liter (ng/l) (greater than or equal to \[\>=\] 300 picograms per milliliter \[pg/ml\]; \>=35.5 picomoles per liter \[pmol/l\]) at screening * women of childbearing potential must meet the following criteria: a) have a negative serum pregnancy test during screening and a negative urine pregnancy test on day 1, b) agree to use acceptable methods of contraception from day 1 to at least 30 days after study intervention discontinuation, c) if only using hormonal contraception, have used it for at least 1 month (30 days) before day 1, and d) agree to perform monthly pregnancy tests to at least 30 days after study intervention discontinuation * 6-minute walking distance (6mwd) \>=150 meter (m) during screening period exclusion criteria: * prior use of prostacyclin (ip)-receptor agonist, prostacyclin, or prostacyclin analog. use of such treatments for vasoreactivity testing is not exclusionary; intermittent use of such treatments for digital ulcers or raynaud's phenomenon is not exclusionary if stopped \> 6 months (180 days) prior to day 1 * treatment with strong inhibitors of cyp2c8 (example, gemfibrozil) within 4 weeks (28 days) prior to day 1 * treatment with another investigational drug planned or taken within 12 weeks (84 days) prior to day 1 * severe coronary heart disease or unstable angina * cerebrovascular events (example, transient ischemic attack, stroke) within 3 months (90 days) prior to day 1

Keywords: right ventricle reverse remodeling magnetic resonance imaging
reducing fasting time in children for sedation

Conditions: Pediatric ALL

Summary: patients are asked to be fasted for certain period of time before sedation to reduce the risk of pulmonary aspiration. however, fasting can be harmful, especially in children who has smaller reserves of energy and fluids compared to the adults. prolonged fasting may increase nausea, vomiting, dehydration, and hypoglycemia. therefore, it is important to minimize prolonged fasting time in pediatric patients. this study is aimed to investigate the safety of minimal fasting time (2 hours) compared to the standard fasting time (4 hours) with gastric ultrasound.


Eligibility criteria:
inclusion criteria: * pediatric patients aged under 36 months * scheduled for elective cardiac echocardiography exclusion criteria: * patients with disease that delay gastric emptying * patients taking medication that delay gastric emptying * structural deformities, or abnormalities that interrupt gastric ultrasound * refuse to participate in the study * sedation is failed or impossible
trial of primary prophylaxis with rhtpo administered to patients with high risk sarcoma receiving intensive chemotherapy

Conditions: Sarcoma

Summary: intensive chemotherapy is often associated with low platelet counts often requiring platelet transfusions to maintain platelet counts. in previous clinical studies administration of rhtpo has been demonstrated to increase platelet counts.

to evaluate the effectiveness of intravenous rhtpo vs. placebo as primary prophylaxis in reducing the cumulative proportion of patients requiring platelet transfusion for severe chemotherapy-induced thrombocytopenia (platelet count \<15,000) during the first four study cycles. to evaluate the severity and duration of thrombocytopenia and neutropenia associated with rhtpo prophylaxis, the impact of rhtpo prophylaxis on health economics/cost effectiveness, and patient quality of life. to assess the safety of multiple iv doses of rhtpo.

Eligibility criteria:
inclusion criteria: * confirmed new diagnosis of moderate or high-grade sarcoma (except leiomyosarcoma of gastrointestinal origin) * must have high risk disease by american joint committee on cancer (ajcc) staging system stage iic, iii, or iv * must have recovered from surgery for a minimum of 2 weeks * must be scheduled for a minimum of 4 cycles of ai therapy * must be 13 years or older * must have ecog performance status of 0, 1, or 2. * must have life expectancy of at least 12 weeks. * left ventricular ejection fraction must be more than 50%. * laboratory data within normal limits. exclusion criteria: * prior front-line standard or experimental therapy for sarcoma * history of bone marrow and or peripheral blood progenitor cell transplantation * prior pelvic radiation or radiation therapy to more than 25% of bone marrow reserves * prior treatment with megakaryocyte growth and differentiation factor * prior treatment with rhtpo * history of platelet disorder * history of myocardial infarction, stroke, pulmonary embolism, or deep vein thrombosis within the past 12 months * pregnant or lactating women * use of anticoagulants such as coumadin, heparin, etc. * known hiv or hepatitis
outcome of treatment of prostate cancer at sohag university hospital between 2017 to 2021

Conditions: Prostate Cancer

Summary: worldwide, prostate cancer is the most commonly diagnosed male cancer and the fourth leading cause of cancer death in men. risk stratification is according to cancer stage, gleason score, and psa level . definitive treatment of localized disease ( low and favorable intermediate risk) includes watchful waiting , active surveillance , radiation therapy , radical prostatectomy and cryotherapy .primary treatment of unfavorable intermediate risk , high risk localized disease and locally advanced prostate cancer , includes both radical prostatectomy (rp) and ebrt + long-term androgen deprivation therapy (adt) .treatment options of metastatic prostate cancer include pain medications, bisphosphonates, hormonal treatment, chemotherapy, radiotherapy, immunotherapy, focused radiation, and other targeted therapies .


Eligibility criteria:
inclusion criteria: * patients at age of 18 years old and above. * all stages and grades of prostate cancer. * epithelial types of prostate cancer. exclusion criteria: * age below 18 years old. * presence of other malignancies.